ALK4290 (AKST4290) 是一种有效的,具有口服活性的 CCR3 抑制剂,对 hCCR3 的 Ki 值为 3.2 nM,详细信息请参考专利文献 US20130261153A1 中的化合物 Example 2。ALK4290 可用于研究新生血管性年龄相关性黄斑变性和帕金森症。
生物活性
ALK4290 (AKST4290) is a potent and orally active CCR3 inhibitor extracted from patent US20130261153A1, compound Example 2, with a K i of 3.2 nM for hCCR3. ALK4290 can be used for the research of neovascular age-related macular degeneration and Parkinsonism.
性状
Solid
IC50 & Target[1][2]
CCR3 3.2 nM (Ki)
运输条件
Room temperature in continental US; may vary elsewhere.
储存方式
Powder -20°C 3 years;4°C 2 years
ClinicalTrial
参考文献
[1]. NIVENS MC, et, al. Use of ccr3-inhibitors. US20130261153A1.[2]. Samanta A, te, al. Emerging Therapies in Neovascular Age-Related Macular Degeneration in 2020. Asia Pac J Ophthalmol (Phila). May-Jun 2020; 9(3):250-259.[3]. Clinical Development of AKST4290 as a Novel Parkinson’s Therapeutic
溶解度数据
In Vitro: DMSO : 50 mg/mL (97.65 mM; ultrasonic and warming and heat to 60°C)配制储备液